Form 4: Phibro CEO Jack Bendheim Executes Stock Sale Plan

Phibro Animal Health Corporation CEO Jack Bendheim and BFI Co., LLC sold a total of 18,607 shares of Class A Common Stock via a Rule 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO of Phibro Animal Health Corporation, reported the sale of 18,607 shares of Class A Common Stock.
• The transactions occurred between May 5, 2026, and May 7, 2026.
• Sales were executed by BFI Co., LLC, an entity over which Mr. Bendheim exercises voting and dispositive power.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and executed under a Rule 10b5-1 plan, which is standard practice for corporate insiders.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without concerns regarding non-public information.

Negatives

• The sale represents a reduction in the insider's beneficial ownership stake in the company.

Risks

• Continued selling by major shareholders or insiders could exert downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a disclosure of insider transaction activity.

Management Comments

• The reporting person disclaims beneficial ownership of the securities held by BFI Co., LLC except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice and generally does not signal a change in company fundamentals or management sentiment regarding the long-term outlook of the animal health sector.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to manage personal liquidity while maintaining compliance with SEC regulations.
• The volume of shares sold is consistent with typical executive diversification strategies observed in mid-cap healthcare and pharmaceutical companies.

Related Party Transactions

• The filing discloses that BFI Co., LLC is an entity controlled by Jack Bendheim, who serves as the President, CEO, and a Director of the Issuer.

Stakeholder Impact

• Minimal impact expected on shareholders as the sales were conducted through a pre-established, automated trading plan.

Next Steps

• Continued monitoring of future Form 4 filings to track any further changes in insider holdings.

Key Dates

Keywords

Phibro Animal Health, PAHC, Insider Trading, Form 4, Jack Bendheim, Rule 10b5-1